This website is intended for US healthcare professionals only

US Medical Affairs

Congress Presentations

Stay informed about the latest scientific and medical research from Axsome.

Nevada Psychiatric Association 31st Annual National Psychopharmacology Update™

Las Vegas, Nevada | February 11 - 14, 2026

AXS-05 | Major Depressive Disorder

Anxiolytic Effects of Dextromethorphan-Bupropion (45mg/105mg): Post Hoc Analyses Across Trials in Major Depressive Disorder

View / Download

AXS-05 | Major Depressive Disorder

Initiating Dextromethorphan-Bupropion (45mg/105mg) in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations

View / Download

AXS-05 | Major Depressive Disorder

Supplemental Information for “Initiating Dextromethorphan-Bupropion (45mg/105mg) in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations” – All Recommendations

View / Download
footer graphic

This site contains scientific information about investigational compounds and/or information about products and/or uses that have not been approved by the US Food and Drug Administration. The safety and efficacy of investigational products and/or investigational uses of approved products has not been established and such investigational products/uses have not and may not be approved for marketing by any health authority.

AXSOME, AUVELITY, SUNOSI, SYMBRAVO and their logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2026 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, New York, NY 10007